These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 20215531

  • 21. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, Zehavi M, Sidi AA, Ramon Y, Tischler T, Livne PM, Friedman E.
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Jernström H, Lubinski J, Lynch HT, Ghadirian P, Neuhausen S, Isaacs C, Weber BL, Horsman D, Rosen B, Foulkes WD, Friedman E, Gershoni-Baruch R, Ainsworth P, Daly M, Garber J, Olsson H, Sun P, Narod SA.
    J Natl Cancer Inst; 2004 Jul 21; 96(14):1094-8. PubMed ID: 15265971
    [Abstract] [Full Text] [Related]

  • 24. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
    Mitra AV, Jameson C, Barbachano Y, Sodha N, Kote-Jarai Z, Javed A, Bancroft E, Fletcher A, Cooper C, Peock S, IMPACT and EMBRACE Collaborators, Easton D, Eeles R, Foster CS.
    Oncol Rep; 2010 Feb 21; 23(2):299-305. PubMed ID: 20043088
    [Abstract] [Full Text] [Related]

  • 25. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M, Friedman E, Gershoni-Baruch R, Brok-Simoni F, Patael Y, Rechavi G, Amariglio N.
    Am J Hematol; 2005 Mar 21; 78(3):203-6. PubMed ID: 15726604
    [Abstract] [Full Text] [Related]

  • 26. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM, O'Malley FP, Milne RL, Andrulis IL, Friedlander ML, Southey MC, Apicella C, Giles GG, Longacre TA.
    J Clin Oncol; 2012 Jan 01; 30(1):19-26. PubMed ID: 22147742
    [Abstract] [Full Text] [Related]

  • 27. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
    Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME.
    J Clin Oncol; 2009 Jan 20; 27(3):433-8. PubMed ID: 19064968
    [Abstract] [Full Text] [Related]

  • 28. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.
    Clin Cancer Res; 2002 Dec 20; 8(12):3776-81. PubMed ID: 12473589
    [Abstract] [Full Text] [Related]

  • 29. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
    Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, Dhani N, Narod S, Akbari M, Moore M, Gallinger S.
    J Clin Oncol; 2015 Oct 01; 33(28):3124-9. PubMed ID: 25940717
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
    Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y, Keidar R, Sagi S, Lahad EL, Auslander R, Beller U.
    Gynecol Oncol; 2004 Feb 01; 92(2):521-4. PubMed ID: 14766242
    [Abstract] [Full Text] [Related]

  • 32. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A, Diaz-Rubio E, de la Hoya M, Caldés T, Teulé A, Lázaro C, Blanco I, Balmaña J, Sánchez-Ollé G, Vega A, Blanco A, Chirivella I, Esteban Cardeñosa E, Durán M, Velasco E, Martínez de Dueñas E, Tejada MI, Miramar MD, Calvo MT, Guillén-Ponce C, Salazar R, San Román C, Urioste M, Benítez J.
    Breast Cancer Res Treat; 2010 Jan 01; 119(1):221-32. PubMed ID: 19370414
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, Weber B, Moller P, Offit K, Kim-Sing C, Friedman E, Randall S, Pasini B, Ainsworth P, Gershoni-Baruch R, Foulkes WD, Klijn J, Tung N, Rennert G, Olopade O, Couch F, Wagner T, Olsson H, Sun P, Weitzel JN, Narod SA.
    Int J Cancer; 2005 Dec 20; 117(6):988-91. PubMed ID: 15986445
    [Abstract] [Full Text] [Related]

  • 35. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
    Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J, Clouston D, Mitchell G, Fox S, Hopper JL, Kathleen Cunningham Consortium for Research in Familial Breast Cancer Consortium, Bolton D.
    Cancer Prev Res (Phila); 2011 Jul 20; 4(7):1002-10. PubMed ID: 21733824
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The relevance of BRCA genetics to prostate cancer pathogenesis and treatment.
    Sundararajan S, Ahmed A, Goodman OB.
    Clin Adv Hematol Oncol; 2011 Oct 20; 9(10):748-55. PubMed ID: 22252577
    [Abstract] [Full Text] [Related]

  • 40. Ductal carcinoma in situ in BRCA mutation carriers.
    Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL.
    J Clin Oncol; 2007 Feb 20; 25(6):642-7. PubMed ID: 17210933
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.